Skip secondary menu

Funding News - Applications to Develop New Therapies for Type 1 Diabetes and Its Complications Requested

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) requests Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) applications to develop new approaches to prevent, treat, and cure type 1 diabetes and its complications. This announcement is made together with 6 other components of the National Institutes of Health (NIH).*

Type 1 diabetes is an autoimmune disease that destroys the insulin-producing cells of the pancreas and affects an estimated one million Americans, usually with onset in childhood or young adulthood. The disease markedly impairs quality of life and shortens lifespan primarily through premature cardiovascular death.

Potential areas of research interest include studies to: develop novel therapeutics, including beta cell replacement therapy, devices, biologics, and other drugs for the treatment of type 1 diabetes and its complications; develop methods to increase the yield of functional and successfully transplantable islets from pancreata including the development of alternative enzymatic approaches to isolate islets and methods to increase the duration for which a pancreas can be utilized; develop improved approaches to xenotransplantation as an unlimited source of islets that would reduce potential complications and enhance graft survival; apply basic research in regenerative medicine to preclinical or clinical treatment of type 1 diabetes and its complications; apply gene therapy strategies to prevent or reverse complications; develop methods for measuring or imaging the pancreatic beta cell mass or inflammation; develop methods for early detection, diagnosis, and quantification of cardiovascular disease; develop high throughput assays based on biologic pathways likely involved in the pathogenesis of type 1 diabetes complications or autoimmunity that could be used to screen molecular libraries for novel therapeutic agents; and develop novel animal models for investigating type 1 diabetes and its complications.

APPLICATION RECEIPT DATE: February 19, 2004.

For more information, potential applicants should contact Dr. Paul Nichols, Program Director, Systems and Cognitive Neuroscience Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2108, Bethesda, MD 20892; telephone: 301-496-9964; fax: 301-401-2060; e-mail: pn13w@nih.gov.

*For a full list of supporting NIH components and a more detailed description of this request for applications, please visit the NIH web site at: http://grants1.nih.gov/grants/guide/rfa-files/RFA-DK-03-020.html.